Research Analysts Set Expectations for LPTX FY2029 Earnings
Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Leap Therapeutics in a research report ...
Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...
Hosted on MSN5d
HC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)
Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Leap Therapeutics (LPTX) and Immunovant (IMVT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Leap Therapeutics (LPTX – Research Report) ...
The Pharma Letter6d
Leap halts gastric cancer program, changes course
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...
Apple downgraded, Rivian initiated: Wall Street's top analyst calls
Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the ...
Investing on MSN6d
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer
Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its DisTinGuish study of sirexatamab combined with tislelizumab and chemotherapy did not ...
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral
H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...